CJC-1295 with Drug Affinity Complex
Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
CJC-1295 DAC is a long-acting version of CJC-1295 that binds to blood albumin, extending its effects to 6-8 days from a single injection. Its clinical development was abandoned after the developer went bankrupt. A death from heart attack occurred during clinical trials in 2006; causality was not established but the FDA required cardiac monitoring for subsequent studies. It has no regulatory approval.
No published studies found on PubMed.
CJC-1295 DAC has no marketing authorisation from any regulatory agency. Phase I data showed sustained growth hormone elevation over 6–8 days and IGF-1 elevation over 9–11 days following a single injection. A death from myocardial infarction occurred during clinical trials in 2006; causality was not established, but the FDA required cardiac monitoring protocols for subsequent studies. ConjuChem Biotechnologies entered bankruptcy in 2010 and no further clinical development has occurred.
No Phase III trials were completed. Products available through unregulated sources lack pharmaceutical quality assurance. The clinical trial death, unresolved safety questions, and absence of further development should be noted when assessing this compound.
Research suggests the same GHRH receptor mechanism as CJC-1295 (#89), but with sustained activity over 6–8 days due to albumin binding. A critical distinction is that this sustained stimulation produces continuously elevated growth hormone and IGF-1 levels rather than the pulsatile pattern seen with shorter-acting GHRH analogues. Research suggests non-pulsatile growth hormone elevation may differ pharmacologically from physiological growth hormone secretion.
Research suggests Phase I data showed sustained growth hormone and IGF-1 elevation lasting 6-8 and 9-11 days respectively after a single injection. No efficacy trials were completed before the developer's bankruptcy in 2010. A critical distinction from shorter-acting GHRH analogues is that the sustained stimulation produces continuously elevated (non-pulsatile) growth hormone — which differs fundamentally from the body's natural pulsatile pattern. Research suggests non-pulsatile growth hormone elevation may carry different risks including insulin resistance and fluid retention. Products from unregulated sources lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Somatropin has been available since the mid-1980s and is one of the most established peptide therapies. It is sold under numerous brand names including Genotropin, Humatrope, Norditropin, and Omnitrope (the first biosimilar approved in the US, 2006). Approved indications include childhood and adult growth hormone deficiency, Turner syndrome, children born small for gestational age, Prader-Willi syndrome, idiopathic short stature, and short stature from chronic kidney disease. Daily injection has been the main burden of somatropin therapy, particularly for paediatric patients who may require years of treatment. This has driven the development of once-weekly alternatives (somatrogon and somapacitan), which are gradually changing the treatment landscape. Annual treatment costs remain substantial, and concerns about misuse in anti-ageing and performance enhancement contexts are ongoing.
Tesamorelin is marketed as Egrifta SV (approved November 2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. In clinical trials, it reduced visceral fat by approximately 15% compared to a 5% increase with placebo, and this reduction was sustained with continued treatment. Tesamorelin occupies a unique niche — it is the only approved GHRH analogue and the only medication specifically approved for HIV-associated lipodystrophy. Beyond its approved indication, it has attracted research interest for potential effects on liver fat, cognitive function, and peripheral neuropathy. Fat reduction reverses when treatment stops, and it is not approved for general weight loss or body composition purposes.
Somatrogon is marketed as Ngenla (approved June 2023) for paediatric growth hormone deficiency in children aged 3 years and older. In the pivotal trial, once-weekly somatrogon produced growth rates equivalent to daily somatropin injections (10.1 cm/year versus 9.8 cm/year), confirming that reducing injection frequency does not compromise growth outcomes. Ngenla represents a meaningful advance for paediatric patients and their families, reducing injections from 365 to 52 per year. Treatment adherence has been a persistent challenge with daily growth hormone, and weekly dosing is expected to improve long-term outcomes through better compliance. Somatrogon competes directly with somapacitan (Sogroya), the other approved weekly growth hormone, creating a new generation of less burdensome treatment options.
